<DOC>
	<DOCNO>NCT00002218</DOCNO>
	<brief_summary>To determine maximum tolerate dose CI-1012 late-stage HIV-1-infected patient . To determine antiretroviral activity CI-1012 add combination therapy . To assess multiple-dose pharmacokinetic characteristic CT-1012 add combination therapy . To assess effect CI-1012 pharmacokinetics antiretroviral agent .</brief_summary>
	<brief_title>A Phase I Maximum Tolerated Dose Study CI-1012 Late-Stage HIV+ Patients</brief_title>
	<detailed_description>Doses escalate base safety assessment : As soon dose meet criteria `` tolerated '' `` tolerate '' , dose escalate terminate , respectively . All patient treat 2 week , follow-up visit schedule 1 week 1 month post-treatment .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<criteria>Inclusion Criteria Patients must : Serological evidence latestage HIV1 infection ( ELISA Western Blot ) . CD4 T cell count less equal 200 mm3 . HIV1 RNA great equal 5,000 copies/mL . Exclusion Criteria Prior Medication : Excluded : AntiHIV treatment within 8 week prior entry . Systemic steroid within 4 week prior entry . Prior Treatment : Excluded : Treatment anticancer agent within 4 week prior study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 1998</verification_date>
	<keyword>HIV-1</keyword>
	<keyword>Dose-Response Relationship , Drug</keyword>
	<keyword>Anti-HIV Agents</keyword>
</DOC>